Xu Tong, Wang Lu, Tao You, Ji Yan, Deng Feng, Wu Xiao-Hong
Department of Prosthodontics, The Affiliated Hospital of Stomatology, Chongqing Medical University, No. 426 Songshibei Road, Yubei District, Chongqing 401147, China; Chongqing Key Laboratory for Oral Diseases and Biomedical Sciences, No. 426 Songshibei Road, Yubei District, Chongqing 401147, China.
Chongqing Key Laboratory for Oral Diseases and Biomedical Sciences, No. 426 Songshibei Road, Yubei District, Chongqing 401147, China; Department of Orthodontics, The Affiliated Hospital of Stomatology, Chongqing Medical University, No. 426 Songshibei Road, Yubei District, Chongqing 401147, China.
Evid Based Complement Alternat Med. 2016;2016:8981650. doi: 10.1155/2016/8981650. Epub 2016 Jan 14.
Osteoporosis has become one of the most prevalent and costly diseases in the world. It is a metabolic disease characterized by reduction in bone mass due to an imbalance between bone formation and resorption. Osteoporosis causes fractures, prolongs bone healing, and impedes osseointegration of dental implants. Its pathological features include osteopenia, degradation of bone tissue microstructure, and increase of bone fragility. In traditional Chinese medicine, the herb Rhizoma Drynariae has been commonly used to treat osteoporosis and bone nonunion. However, the precise underlying mechanism is as yet unclear. Osteoprotegerin is a cytokine receptor shown to play an important role in osteoblast differentiation and bone formation. Hence, activators and ligands of osteoprotegerin are promising drug targets and have been the focus of studies on the development of therapeutics against osteoporosis. In the current study, we found that naringin could synergistically enhance the action of 1α,25-dihydroxyvitamin D3 in promoting the secretion of osteoprotegerin by osteoblasts in vitro. In addition, naringin can also influence the generation of osteoclasts and subsequently bone loss during organ culture. In conclusion, this study provides evidence that natural compounds such as naringin have the potential to be used as alternative medicines for the prevention and treatment of osteolysis.
骨质疏松症已成为世界上最普遍且代价高昂的疾病之一。它是一种代谢性疾病,其特征是由于骨形成与骨吸收之间的失衡导致骨量减少。骨质疏松症会引发骨折、延长骨愈合时间,并阻碍牙种植体的骨整合。其病理特征包括骨质减少、骨组织微观结构退化以及骨脆性增加。在传统中医中,骨碎补常用于治疗骨质疏松症和骨不连。然而,其确切的潜在机制尚不清楚。骨保护素是一种细胞因子受体,已证明在成骨细胞分化和骨形成中起重要作用。因此,骨保护素的激活剂和配体是有前景的药物靶点,并且一直是抗骨质疏松症治疗药物开发研究的重点。在本研究中,我们发现柚皮苷可在体外协同增强1α,25 - 二羟基维生素D3促进成骨细胞分泌骨保护素的作用。此外,柚皮苷在器官培养过程中还可影响破骨细胞的生成以及随后的骨质流失。总之,本研究提供了证据表明柚皮苷等天然化合物有潜力用作预防和治疗骨质溶解的替代药物。